Highlights of weekly biotech stock moves

ALK-Abello A/S (CSE:ALK-B) was down DKK3 to DKK416 last week after FDA accepted for review a BLA from partner Merck & Co. Inc. (NYSE:MRK) for Ragweed Allergy Immunotherapy Tablet (AIT) in adults with ragweed-induced allergic rhinitis. The pharma said it expects a decision in 1H14.

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) gained $0.82 (11%) to $8.34 on Tuesday after the U.S. Drug Enforcement Agency issued a final rule establishing obesity drug Belviq lorcaserin as a class IV controlled substance, in line with the company's proposed and FDA's requested classification. Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) plans to launch the drug in the U.S. in June...